Amphetamine

Saniona Launches New Video Series to Highlight the Impact of Prader-Willi Syndrome and Hypothalamic Obesity on Patients and Caregivers

Retrieved on: 
Monday, May 10, 2021
Clinical medicine, Health, Medicine, Congenital disorders, Amphetamine, Bariatrics, Body shape, Nutrition, Obesity, Prader–Willi syndrome, Prader

The company\xe2\x80\x99s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain.

Key Points: 
  • The company\xe2\x80\x99s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain.
  • Ultimately CP survivors with hypothalamic injury report at least three times higher 20-year mortality than CP survivors without hypothalamic injury.
  • Many HO patients are treated with approaches used for general obesity such as surgery, medication and lifestyle counseling, but these are often ineffective.
  • It occurs most often in children and older adults, creating a burden for both patients and families.\n'

Global Narcolepsy Epidemiology and Patient Flow Report 2021: Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries for 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Health, Biotechnology, Sleep disorders, Amphetamine, Narcolepsy, Medicine, Clinical medicine, Branches of biology

b'The "Global Narcolepsy Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Narcolepsy Epidemiology and Patient Flow Analysis - 2021, provides Narcolepsy epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Narcolepsy Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Narcolepsy Epidemiology and Patient Flow Analysis - 2021, provides Narcolepsy epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Narcolepsy patients, history of the disease at the population level (Narcolepsy prevalence, Narcolepsy incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Narcolepsy patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Narcolepsy market sizing, assessing market potential, and developing drug forecast models\nIdentify Narcolepsy patients segments through age groups, gender, and disease sub-types\n'

NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)

Retrieved on: 
Wednesday, May 5, 2021
Psychoactive drugs, Amphetamine, Stimulants, Chloroarenes, Imidazolines, Mazindol, Narcolepsy, Attention deficit hyperactivity disorder, Drug

EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

Key Points: 
  • EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).
  • "Earlier this year, we were granted a similar patent in Canada, and our U.S. patent application is pending review.
  • Additionally, this newly issued patent augments the Orphan Drug Designations that we have for Quilience in both Europe and the U.S.
  • The Company\'s lead product candidate, Quilience is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy.

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children

Retrieved on: 
Tuesday, May 4, 2021
Health sciences, Childhood psychiatric disorders, Health, Psychiatry, Attention deficit hyperactivity disorder, Amphetamine, Methylphenidate, Medication, Pharmaceutical industry, Stimulant, Prescription drug

The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.

Key Points: 
  • The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.
  • In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant.
  • "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient.
  • In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents.

Phenomix Sciences Signs Exclusive Technology Licensing Deal With Mayo Clinic for Obesity Phenotype Blood Test

Retrieved on: 
Tuesday, May 4, 2021
Health, Diabetes, Other Health, Fitness & Nutrition, General Health, Biotechnology, Branches of biology, Systems biology, Amphetamine, Bariatrics, Body shape, Nutrition, Obesity, Metabolomics, Mayo Clinic, Biology

b'Biomedical startup company Phenomix Sciences (Phenomix) has signed an exclusive technology licensing agreement with Mayo Clinic for a novel blood test that accurately predicts obesity phenotypes.

Key Points: 
  • b'Biomedical startup company Phenomix Sciences (Phenomix) has signed an exclusive technology licensing agreement with Mayo Clinic for a novel blood test that accurately predicts obesity phenotypes.
  • The multi-level \xe2\x80\x9comics\xe2\x80\x9d MyPhenome\xe2\x84\xa2 test leverages technology developed at Mayo Clinic to analyze genomics, metabolomics and hormone levels.
  • Its AI-driven algorithmic solution identifies four specific obesity phenotypes to give doctors the ability to prescribe more precise anti-obesity treatments.
  • Obesity has its roots in DNA, but there is also a complicated web connecting obesity to age, race, and gender, as well as education and socioeconomic status.

OWP Pharmaceuticals Announces Patent Application for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder

Retrieved on: 
Thursday, April 22, 2021
Psychoactive drugs, Amphetamine, Psychiatry, Branches of biology, Childhood psychiatric disorders, Methylphenidate, Nootropics, Educational psychology, Attention deficit hyperactivity disorder, Atomoxetine

b"NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.

Key Points: 
  • b"NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.
  • OWP announced today that it has submitted for U.S. patent protection, for the first-ever oral suspension of atomoxetine hydrochloride.
  • The medication is widely prescribed by healthcare providers in psychiatry for ADHD, and it is indicated for treatment in children 6 years and older and adults.
  • Some individuals with ADHD also display difficulty regulating emotions or problems with executive function.

COVID-19 Has Demonstrated Dangers of Comorbidities, Including Obesity

Retrieved on: 
Monday, April 19, 2021
Health, Clinical medicine, Articles, Amphetamine, Bariatrics, Body shape, Nutrition, Obesity, COVID-19, Comorbidity, Diabetes

One major insight finds obesity is a serious factor in both infections and consequential health problems.

Key Points: 
  • One major insight finds obesity is a serious factor in both infections and consequential health problems.
  • (1)\nStuart Long, CEO of InfoBionic , says that one of the most productive solutions for patients at risk is remote monitoring.
  • "The comorbidities that put people at risk include conditions like diabetes and lung disease, but obesity has clearly emerged as a catalyst for some of COVID-19\'s worst outcomes.
  • (2) The underlying pathologies of obesity only compound the virus\' effects.

Global Anti-obesity Drugs Market 2021-2025 - Limited Number of Approved Drugs and Use of Bariatric Surgery Limited for Morbid Obesity to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 13, 2021
Health, Pharmaceutical, Medical specialties, Surgery, Clinical medicine, Obesity, Nutrition, Amphetamine, Bariatrics, Body shape, Bariatric surgery

b'The "Global Anti-obesity Drugs Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe anti-obesity drugs market is poised to grow by $ 454.51 mn during 2021-2025 decelerate at a CAGR of 5% during the forecast period.\nThe market is driven by the limited number of approved drugs and use of bariatric surgery limited for morbid obesity.\nThe reports on anti-obesity drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Key Points: 
  • b'The "Global Anti-obesity Drugs Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe anti-obesity drugs market is poised to grow by $ 454.51 mn during 2021-2025 decelerate at a CAGR of 5% during the forecast period.\nThe market is driven by the limited number of approved drugs and use of bariatric surgery limited for morbid obesity.\nThe reports on anti-obesity drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • This is to help companies strategize and leverage on all forthcoming growth opportunities.\nThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\n'

Brain Cells Decide on Their Own When to Release Pleasure Hormone

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Amphetamine, Neurotransmitters, Dopamine, Phenethylamines, Neuron, Parkinson's disease, Area postrema, Ventral tegmental area

Led by researchers at NYU Grossman School of Medicine, the new study showed that dopamine-releasing brain cells respond to their own signals to regulate the hormone's output.

Key Points: 
  • Led by researchers at NYU Grossman School of Medicine, the new study showed that dopamine-releasing brain cells respond to their own signals to regulate the hormone's output.
  • Because the death of dopamine-releasing brain cells is a key factor in Parkinson's disease, the new findings provide insight into why these cells die in the movement disorder, the researchers say.
  • They injected some of the brain cells with Botox, a toxin that blocks nerve cells from sending chemical messages to neurons and other cells.
  • If the neurons were in fact controlled by neighboring dopamine cells, then dopamine release would remain unaffected because the treated cells would still receive dopamine signals from the untreated cells nearby.

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

Retrieved on: 
Friday, April 2, 2021
Psychoactive drugs, Psychiatry, Amphetamine, Attention deficit hyperactivity disorder, Methylphenidate, Medicine, Childhood psychiatric disorders, Stimulant, Medication, Attention deficit hyperactivity disorder management, Attention deficit hyperactivity disorder controversies

Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.

Key Points: 
  • Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.
  • Qelbree provides prescribing physicians and patients living with ADHD a therapy that is not a controlled substance with proven efficacy and a tolerable safety profile.
  • This approval offers a novel once a day sprinkleable non-stimulant that can be a great option for children and adolescents with ADHD.
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.